Can Biopharma Steer Through the Stormy Seas? - The year 2009 was marked by recession, industry megamergers, and venture-capital scarcity. How did biopharmaceutical professionals fare? - BioPharm

ADVERTISEMENT

Can Biopharma Steer Through the Stormy Seas?
The year 2009 was marked by recession, industry megamergers, and venture-capital scarcity. How did biopharmaceutical professionals fare?


BioPharm International
Volume 23, Issue 1

ARE YOU SECURE AND SATISFIED?


Figure 3. Do you feel secure in your current job?
Because of the economic situation and stresses on the pharmaceutical industry, we expected our survey respondents to have serious concerns about job security. Surprisingly, their sense of security hasn't changed much compared to last year. In 2009, 68% of respondents said they feel "secure," "very secure," or "extremely secure" in their current jobs (Figure 3), only down a little bit from last year's figure of 71%.


Figure 4. Effect of downsizing, restructuring, a merger, or an acquisition
Industry consolidation is affecting companies throughout the industry, however. More than half (53%) of our respondents have been through a merger, acquisition, or downsizing within the last two years), although almost half of them (49%) said it had no significant effect on them (Figure 4). The rest said their job responsibilities changed (32%) as a result of a merger or downsizing activity or that they chose to leave their companies voluntarily (8%).


Figure 5. Reasons for possibly leaving current position
So are biotech professionals still confident enough to risk job changes in this economy? Our survey shows that a lot of people are sitting tight. The majority of respondents (65%) said they are not likely to leave their jobs in the next 12 months, compared to 60% last year. For those who expect to change jobs, the reasons are split between positive and negative: about a third (32%) cited involuntary departure but 25% said they would make a move for a better salary or more satisfying work (20%), as shown in Figure 5.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here